August 26, 2021 Kinnate Biopharma Inc.
Exhibit 10.2
|
|
August 26, 2021
Kinnate Biopharma Inc.
000 Xxxxxxxxxx Xxxxxx, Xxxxx 000
The Presidio of San Francisco
San Francisco, California 94129
Attn: Xxxx Xxxxxx
Re: Net Office Lease, dated as of August 5, 2021 (the “Lease”) by and between Kinnate Biopharma Inc., a Delaware corporation, as Tenant, and the Presidio Trust, as Landlord, for the Premises known as Building 103, Suite 150, located at 000 Xxxxxxxxxx Xxxxxx, xxx Xxxxxxxx xx Xxx Xxxxxxxxx, Xxx Xxxxxxxxx, Xxxxxxxxxx
Dear Xx. Xxxxxx,
Provided that no Default (as defined in the Lease) has occurred and is continuing, upon completion of certain tenant improvements in accordance with the requirements within the Lease, which shall include construction of a boardroom within the Premises (the “Tenant Improvements”), Tenant will receive a one-time Base Rent credit of $85,000, which shall be credited by Landlord against monthly Base Rent accruing after completion of the Tenant Improvements. Tenant agrees that it will use commercially reasonable efforts to complete the Tenant Improvements in a prompt and diligent manner,
This letter agreement may be executed and delivered in any number of counterparts, each of which so executed and delivered is deemed to be an original and all of which will constitute one and the same instrument. This letter agreement may be executed and delivered using electronic signature(s) in accordance with applicable law, and electronic signature(s) are deemed to be original signatures for purposes of this letter agreement and all matters related thereto, with such electronic signature(s) having the same legal effect as original signature(s).
This letter agreement will not be effective or binding upon either Landlord or Tenant until it has been fully executed and delivered by both Landlord and Xxxxxx.
Sincerely,
PRESIDIO TRUST,
a wholly-owned government corporation of the United States of America
/s/ Xxxx Xxxxxx |
| |
Xxxx Xxxxxx, Deputy Chief Business Officer | | |
| | |
| | |
Agreed and acknowledged: | | |
Kinnate Biopharma Inc. | | |
A Delaware corporation | | |
By: | /s/ Xxxx Xxxxxx |
| |
Name: | Xxxx Xxxxxx | | |
Title: | CEO | | |
Date: | 10/12/2021 | | |
